Why Is AZENTA INC (AZTA) Stock Up Today?

Azenta Inc (AZTA) shares rose 18.59% to close at $48.01. The primary driver was a strong fourth quarter performance, where the company beat revenue and earnings estimates, alongside the announcement of strategic acquisitions and a fiscal 2027 outlook that exceeded market consensus.

What Happened

Azenta reported fourth quarter revenue of $167 million, which surpassed estimates by $6.8 million. The company posted a non-GAAP EPS of $0.28, beating the $0.11 estimate by $0.17. Although the company reported a GAAP loss of $0.14 per share, the positive surprise in adjusted metrics drove the share price higher. Azenta filed a Form 8-K with the SEC on November 10, 2026, to disclose these results.

The company provided a fiscal 2027 revenue guidance range of $648 million to $660 million, which is above the consensus estimate of $639.25 million. Management also projected 3% to 5% organic revenue growth for the upcoming fiscal year. In addition to the financial results, Azenta announced the acquisition of SynPlexity, a gene library maker, and secured an exclusive license with Elegen for DNA synthesis technology. The company also outlined strategic investments to advance its GENEWIZ capabilities.

What The Data Shows

The stock opened at $43.00, representing a 6.2% gap up from the prior close of $40.48. The session high reached $48.12 at 10:20 AM ET, while the session low was $41.55 at 7:15 AM ET. Volume stood at 0.3 million shares, which is 0.4 times the three-month daily average. The company has a market capitalization of $1.8 billion and remains unprofitable on a trailing twelve-month basis, with an EPS of -$2.46 and a net margin of -20.0%. Revenue grew 4.8% over the trailing twelve months. The stock has a beta of 1.47 and a 52-week range of $15.93 to $46.41. On November 11, 2026, the stock printed three fresh 52-week highs and four fresh 52-week lows.

What To Watch

Investors will monitor the company’s execution on its fiscal 2027 organic growth targets and the integration of the SynPlexity acquisition. The upcoming first quarter results will be key to validating the 3% to 4% organic revenue growth projection for the period.